menu
    • menu
    [{"orgOrder":0,"company":"CellVax Therapeutics","sponsor":"Society of Urologic Oncology Clinical Trials Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"FK-PC101","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"CellVax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CellVax Therapeutics \/ Society of Urologic Oncology Clinical Trials Consortium","highestDevelopmentStatusID":"8","companyTruncated":"CellVax Therapeutics \/ Society of Urologic Oncology Clinical Trials Consortium"},{"orgOrder":0,"company":"CellVax Therapeutics","sponsor":"Theragent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"FK-PC101","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"CellVax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CellVax Therapeutics \/ CellVax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CellVax Therapeutics \/ CellVax Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by CellVax Therapeutics

    Menu

    CellVax Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CellVax Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            CellVax Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FK-PC101

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Society of Urologic Oncology Clinical Trials Consortium

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CellVax Announces FDA Clearance for FK-PC101, a Novel Personalized Cancer Immunotherapy

                            Details : FK-PC101 is novel personalized cancer immunotherapy which is being evaluated in phase 2 clinical trials for high-risk prostate cancer post-radical prostatectomy.

                            Brand Name : FK-PC101

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 29, 2024

                            Lead Product(s) : FK-PC101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Society of Urologic Oncology Clinical Trials Consortium

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CellVax Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            CellVax Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FK-PC101

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Theragent

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent

                            Details : FK-PC101 is a novel cancer immunotherapy, it utilizes the patient's own cells to create specific tumor presenting cell. It is being evaluated in phase 2 clinical trials for the treatment of prostate cancer.

                            Brand Name : FK-PC101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 20, 2023

                            Lead Product(s) : FK-PC101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Theragent

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth